Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer.

Krishna S, Ulrich P, Wilson E, Parikh F, Narang P, Yang S, Read AK, Kim-Schulze S, Park JG, Posner M, Wilson Sayres MA, Sikora A, Anderson KS.

Cancer Res. 2018 Aug 28. pii: canres.0163.2018. doi: 10.1158/0008-5472.CAN-18-0163. [Epub ahead of print]

PMID:
30154146
2.

Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases.

Michlmayr D, Pak TR, Rahman AH, Amir ED, Kim EY, Kim-Schulze S, Suprun M, Stewart MG, Thomas GP, Balmaseda A, Wang L, Zhu J, Suaréz-Fariñas M, Wolinsky SM, Kasarskis A, Harris E.

Mol Syst Biol. 2018 Aug 27;14(8):e7862. doi: 10.15252/msb.20177862.

3.

Anhedonia as a clinical correlate of inflammation in adolescents across psychiatric conditions.

Freed RD, Mehra LM, Laor D, Patel M, Alonso CM, Kim-Schulze S, Gabbay V.

World J Biol Psychiatry. 2018 Aug 16:1-11. doi: 10.1080/15622975.2018.1482000. [Epub ahead of print]

PMID:
29843560
4.

Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV.

Robinson-Papp J, Nmashie A, Pedowitz E, Benn EKT, George MC, Sharma S, Murray J, Machac J, Heiba S, Mehandru S, Kim-Schulze S, Navis A, Elicer I, Morgello S.

AIDS. 2018 Jun 1;32(9):1147-1156. doi: 10.1097/QAD.0000000000001802.

PMID:
29596112
5.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
6.

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.

Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW.

Transl Psychiatry. 2017 Mar 21;7(3):e1065. doi: 10.1038/tp.2017.31.

7.

Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity.

Yin W, Duluc D, Joo H, Xue Y, Gu C, Wang Z, Wang L, Ouedraogo R, Oxford L, Clark A, Parikh F, Kim-Schulze S, Thompson-Snipes L, Lee SY, Beauregard C, Woo JH, Zurawski S, Sikora AG, Zurawski G, Oh S.

Cancer Immunol Res. 2016 Oct;4(10):823-834. Epub 2016 Aug 2.

8.

Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.

Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, Zhang DY, Kim-Schulze S, Kao J, Gnjatic S, Oh S, Posner MR, Sikora AG.

Cancer Res. 2014 Dec 15;74(24):7205-16. doi: 10.1158/0008-5472.CAN-14-1913. Epub 2014 Oct 15.

9.

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.

Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL.

J Immunother Cancer. 2014 Jan 27;2:1. doi: 10.1186/2051-1426-2-1. eCollection 2014.

10.

Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules.

Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A.

Hum Gene Ther. 2014 May;25(5):452-60. doi: 10.1089/hum.2013.217. Epub 2014 Mar 26.

11.

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.

Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S.

Ann Surg Oncol. 2010 Mar;17(3):718-30. doi: 10.1245/s10434-009-0809-6.

PMID:
19915919
12.

Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand.

Kim HS, Kim-Schulze S, Kim DW, Kaufman HL.

Cancer Res. 2009 Nov 1;69(21):8516-25. doi: 10.1158/0008-5472.CAN-09-2522. Epub 2009 Oct 20.

13.

Gene therapy for antitumor vaccination.

Kim-Schulze S, Kaufman HL.

Methods Mol Biol. 2009;542:515-27. doi: 10.1007/978-1-59745-561-9_27.

PMID:
19565920
14.

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL.

J Clin Oncol. 2009 Jun 1;27(16):2645-52. doi: 10.1200/JCO.2008.19.1106. Epub 2009 Apr 13.

15.

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S.

J Transl Med. 2009 Jan 7;7:2. doi: 10.1186/1479-5876-7-2.

16.

Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.

Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL.

Mol Ther. 2009 Feb;17(2):380-8. doi: 10.1038/mt.2008.249. Epub 2008 Nov 25.

17.

Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer.

Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, Kaufman HL.

J Immunol. 2008 Dec 1;181(11):8112-9.

18.

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.

Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL.

Clin Cancer Res. 2008 Aug 1;14(15):4843-9. doi: 10.1158/1078-0432.CCR-08-0276.

19.

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.

Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J.

J Transl Med. 2007 Nov 26;5:60.

20.

Cytokine therapy for cancer.

Kim-Schulze S, Taback B, Kaufman HL.

Surg Oncol Clin N Am. 2007 Oct;16(4):793-818, viii. Review.

PMID:
18022545
21.

The tumour microenvironment and implications for cancer immunotherapy.

Petrulio CA, Kim-Schulze S, Kaufman HL.

Expert Opin Biol Ther. 2006 Jul;6(7):671-84. Review.

PMID:
16805707
22.

4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL.

Vaccine. 2006 Jun 5;24(23):4975-86. Epub 2006 Mar 31.

23.

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.

PMID:
16505437
24.

Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells.

Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, Cortesini R, Suciu-Foca N.

J Immunol. 2006 Mar 1;176(5):2790-8.

25.

Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells.

Kim-Schulze S, Seki T, Vlad G, Scotto L, Fan J, Colombo PC, Liu J, Cortesini R, Suciu-Foca N.

Am J Transplant. 2006 Jan;6(1):76-82.

26.

Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies.

Colovai AI, Vasilescu ER, Foca-Rodi A, Kim-Schulze S, Hussaini N, D'agati VD, Markowitz GS, Wang C, Cohen DJ, Hardy MA, Suciu-Foca N.

Hum Immunol. 2005 May;66(5):501-12. Epub 2005 Feb 19.

PMID:
15935887
27.

Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection.

Liu J, Liu Z, Witkowski P, Vlad G, Manavalan JS, Scotto L, Kim-Schulze S, Cortesini R, Hardy MA, Suciu-Foca N.

Transpl Immunol. 2004 Dec;13(4):239-47.

PMID:
15589736
28.

Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review.

Suciu-Foca N, Manavalan JS, Scotto L, Kim-Schulze S, Galluzzo S, Naiyer AJ, Fan J, Vlad G, Cortesini R.

Int Immunopharmacol. 2005 Jan;5(1):7-11. Review.

PMID:
15589454
29.

Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells.

Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, Kim-Schulze S, Fang J, Favera RD, Cortesini R, Suciu-Foca N.

Hum Immunol. 2004 Nov;65(11):1297-306.

PMID:
15556680
30.

Role of regulatory and suppressor T-cells in the induction of ILT3+ ILT4+ tolerogenic endothelial cells in organ allografts.

Cortesini NS, Colovai AI, Manavalan JS, Galluzzo S, Naiyer AJ, Liu J, Vlad G, Kim-Schulze S, Scotto L, Fan J, Cortesini R.

Transpl Immunol. 2004 Sep-Oct;13(2):73-82. Review. No abstract available.

PMID:
15380537
31.

Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity.

Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, Marboe C, Mancini D, Cortesini R, Suciu-Foca N.

Int Immunol. 2004 Aug;16(8):1055-68. Epub 2004 Jun 28.

PMID:
15226269
33.

Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells.

Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, Schnaper HW.

Circulation. 1996 Sep 15;94(6):1402-7.

PMID:
8822999
34.

Oestrogen and endothelial cell angiogenic activity.

Schnaper HW, McGowan KA, Kim-Schulze S, Cid MC.

Clin Exp Pharmacol Physiol. 1996 Mar;23(3):247-50. Review.

PMID:
8934616

Supplemental Content

Loading ...
Support Center